Get started
Author

Manuela Zonca

A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity
2018 · Marta Compte, Seandean Lykke Harwood, et al. · Nature Communications · 145
PDF
High resolution live cell imaging reveals novel cyclin A2 degradation foci involving autophagy
2014 · Abdelhalim Loukil, Manuela Zonca, et al. · Journal of Cell Science · 42
APRIL promotes breast tumor growth and metastasis and is associated with aggressive basal breast cancer
2015 · Araceli García-Castro, Manuela Zonca, et al. · Carcinogenesis · 38
NFκB activation by modified vaccinia virus as a novel strategy to enhance neutrophil migration and HIV-specific T-cell responses
2015 · Mauro Di Pilato, Ernesto Mejías-Pérez, et al. · Proceedings of the National Academy of Sciences · 35
An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity
2021 · Marta Compte, Seandean L. Harwood, et al. · Clinical Cancer Research · 27
APRIL and BAFF Proteins Increase Proliferation of Human Adipose-Derived Stem Cells Through Activation of Erk1/2 MAP Kinase
2011 · Manuela Zonca, Pablo Mancheño-Corvo, et al. · Tissue Engineering Part A · 23
Abstract 5013: NG-641: An oncolytic T-SIGn virus targeting cancer-associated fibroblasts in the stromal microenvironment of human carcinomas
2019 · Brian R. Champion, Matthieu Besneux, et al. · Cancer Research · 11
Distinct Trafficking of Cell Surface and Endosomal TIM ‐1 to the Immune Synapse
2015 · Meriem Echbarthi, Manuela Zonca, et al. · Traffic · 8
PDF
1003 Tumor-specific replication and immunoactivity of aCD40-producing T-SIGn vectors
2024 · Maria Stella Sasso, Meg Snowden, et al. · Journal for ImmunoTherapy of Cancer · 1
Abstract 2740: Safe and effective delivery of antibody fragments to the solid tumor microenvironment
2023 · Rachel Bergin, Amandine Pelletier, et al. · Cancer Research · 1
Safety, Tolerability, and Immunogenicity of NeomiVac, a Next-Generation mRNA–Lipid Nanoparticle Vaccine Comprising a Novel Ionisable Lipid: A First-In-Human, Phase 1, Dose-Escalation Trial
2026 · Angelica Vaccaro, Jordon Rolt, et al. · SSRN Electronic Journal
Preclinical Evaluation and Phase I Clinical Trial of Neomivac, a Lipid Nanoparticle mRNA Vaccine
2026 · Angelica Vaccaro, Jordon Rolt, et al. · SSRN Electronic Journal
Abstract 5746: Flexible tumor-specific cytokine and antigen delivery through the T-SIGn vector platform enables effective CAR-T cell therapy against solid tumors
2023 · Maria Stella Sasso, Rachel Bergin, et al. · Cancer Research
Supplementary Methods from An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity
2023 · Marta Compte, Seandean L. Harwood, et al.
Table S6 from An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity
2023 · Marta Compte, Seandean L. Harwood, et al.
Figure S8 from An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity
2023 · Marta Compte, Seandean L. Harwood, et al.
Figure S13 from An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity
2023 · Marta Compte, Seandean L. Harwood, et al.
PDF
Figure S4 from An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity
2023 · Marta Compte, Seandean L. Harwood, et al.
Figure S7 from An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity
2023 · Marta Compte, Seandean L. Harwood, et al.
Table S3 from An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity
2023 · Marta Compte, Seandean L. Harwood, et al.
Table S1 from An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity
2023 · Marta Compte, Seandean L. Harwood, et al.
Table S5 from An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity
2023 · Marta Compte, Seandean L. Harwood, et al.
Figure S6 from An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity
2023 · Marta Compte, Seandean L. Harwood, et al.
Figure S1 from An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity
2023 · Marta Compte, Seandean L. Harwood, et al.
PDF
Table S4 from An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity
2023 · Marta Compte, Seandean L. Harwood, et al.
Works count: 64
Citation count: 331
H-index: 8
I10-index: 7
Year
Topic
Type